Spots Global Cancer Trial Database for A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
Official Title: A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment
Study ID: NCT00446069
Interventions
Study Description
Brief Summary: The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site 51, Kaunas, , Lithuania
Site 50, Vilnius, , Lithuania
Site 63, Bielsko-Biaia, , Poland
Site 60, Bydgoszcz, , Poland
Site 62, Poznań, , Poland
Site 61, Warszawa, , Poland
Site 64, Wrocław, , Poland
Site 65, Włocławek, , Poland
Contact Details
Name: Christine Andersen, MSc Pharm
Affiliation: Egalet A/S
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
